Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification

被引:2
|
作者
Feng, Lijuan [1 ]
Kan, Ying [1 ]
Wang, Wei [1 ]
Wang, Chao [2 ]
Zhang, Hui [3 ]
Xie, Peng [4 ]
Yang, Jigang [1 ]
机构
[1] Capital Med Univ, Beijing Friendship Hosp, Dept Nucl Med, 95 Yong Rd, Beijing 100050, Peoples R China
[2] SinoUn Healthcare Inc, Beijing 100192, Peoples R China
[3] Tsinghua Univ, Sch Med, Dept Biomed Engn, Beijing 100084, Peoples R China
[4] Hebei Med Univ, Hosp 3, Dept Nucl Med, Shijiazhuang 050051, Peoples R China
关键词
Event-free survival; Neuroblastoma; Nomogram; Overall survival; Prognosis; MITOSIS-KARYORRHEXIS INDEX; CLASSIFICATION;
D O I
10.1007/s00432-023-05398-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeTo develop and validate a nomogram for predicting survival in intermediate- and high-risk neuroblastoma patients and to compare the accuracy of the nomogram in predicting survival with Children's Oncology Group (COG) risk stratification.MethodsA total of 885 intermediate- and high-risk neuroblastoma patients were enrolled in this study, including 243 patients from our hospital (the training set) and 642 patients from the TARGET database (the validation set). The factors related to event-free survival (EFS) and overall survival (OS) in neuroblastoma were determined to construct the nomogram by Cox regression analysis. The C-index, calibration curves, and area under the time-dependent receiver operating characteristic curves (AUCs) were used to assess the predictive performance of the nomogram.ResultsInternational Neuroblastoma Staging System stage and Mitosis-karyorrhexis index (MKI) were significant unfavorable factors for EFS, while MKI and MYCN status were significant unfavorable factors for OS. The C-index of the nomogram was 0.621 and 0.586 for predicting EFS, 0.650 and 0.570 for predicting OS in the training and validation sets, respectively. The calibration curves revealed good agreement in the EFS and OS predicted by the nomogram. The AUCs of the nomogram for 1-, 2-, 3-year EFS and OS were 0.633, 0.669, 0.604 and 0.672, 0.670, 0.702 in the training set, respectively. Moreover, the nomogram was able to classify patients into two groups according to risk scores, with the "high-risk" group having a lower survival rate than the "intermediate-risk" group. And the nomogram performed better than the COG risk stratification, which had a C-index of 0.537, 0.502 and 0.565, 0.572 for predicting EFS, OS in the training and validation sets, respectively.ConclusionWe developed and validated a prognostic nomogram for intermediate- and high-risk neuroblastoma patients that clinicians can use to make more informed decisions for individual patients.
引用
收藏
页码:16377 / 16390
页数:14
相关论文
共 50 条
  • [41] Improved risk stratification by PET-based intratumor heterogeneity in children with high-risk neuroblastoma
    Li, Chao
    Wang, Shaoyan
    Li, Can
    Yin, Yafu
    Feng, Fang
    Fu, Hongliang
    Wang, Hui
    Chen, Suyun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] The Development and Validation of a Nomogram for Predicting Cancer-Specific Survival and a Risk Stratification System for Patients with Primary Gastrointestinal Melanoma
    Qiu, Shaotian
    Chen, Rui
    Yu, Zhenjun
    Shao, Shuai
    Yuan, Haixia
    Han, Tao
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2023, 34 (08): : 850 - 858
  • [43] Rituximab is Highly Effective in Children and Adolescents with Intermediate- and High-Risk Burkitt Lymphoma
    Zhen, Z.
    Zhu, J.
    Wang, J.
    Lu, S.
    Sun, F.
    Huang, J.
    Sun, X.
    PEDIATRIC BLOOD & CANCER, 2018, 65 : S215 - S215
  • [44] Focal therapy in intermediate- and high-risk prostate cancer
    Nicolai A. Huebner
    Stephan Korn
    Pawel Rajwa
    Shahrokh F. Shariat
    memo - Magazine of European Medical Oncology, 2023, 16 : 247 - 250
  • [45] Focal therapy in intermediate- and high-risk prostate cancer
    Huebner, Nicolai A.
    Korn, Stephan
    Rajwa, Pawel
    Shariat, Shahrokh F.
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 (04) : 247 - 250
  • [46] Overview of Management of Intermediate- and High-Risk Pulmonary Embolism
    Tapson, Victor F.
    Weinberg, Aaron S.
    CRITICAL CARE CLINICS, 2020, 36 (03) : 449 - +
  • [47] Development and validation of a nomogram for predicting high-burnout risk in nurses
    Ning, Meng
    Chen, Zengyu
    Yang, Jiaxin
    Li, Xuting
    Yu, Qiang
    Huang, Chongmei
    Li, Yamin
    Tian, Yusheng
    JOURNAL OF CLINICAL NURSING, 2025, 34 (04) : 1338 - 1350
  • [48] Efficacy of complete resection for high-risk neuroblastoma: A children's cancer group study
    Adkins, ES
    Sawin, R
    Gerbing, RB
    London, WB
    Matthay, KK
    Haase, GM
    JOURNAL OF PEDIATRIC SURGERY, 2004, 39 (06) : 931 - 936
  • [49] Outcome of children with high-risk neuroblastoma
    Fluchel, M
    Hawkins, DS
    Felgenhauer, J
    Douglas, JJ
    Sanders, JE
    Park, JR
    PEDIATRIC RESEARCH, 2003, 53 (04) : 300A - 301A
  • [50] 'ULTRA-HIGH-RISK' NEUROBLASTOMA SUBGROUP: A TOOL TO PREDICT SURVIVAL IN CHILDREN WITH NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA
    Yadgarov, Mikhail
    Matveev, Nikolai
    Kailash, Chaurasiya
    Shamanskaya, Tatyana
    Kachanov, Denis
    Likar, Yury
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S221 - S221